Picture supply: Getty Photos
When trying to find UK shares to purchase, profitability needs to be one of many first areas of analysis. Whether or not on the lookout for progress alternatives or dividend shares, profitability is a crucial measure of a inventory’s long-term potential.
To measure profitability, buyers usually take a look at a number of key return-focused metrics. The most typical are return on fairness (ROE), return on capital employed (ROCE) and return on property (ROA). These measures are only when evaluating shares in the identical trade, as this has a notable impact on their relevance.
Along with measuring return-based metrics, it’s vital to take a look at margins. These consider how properly a enterprise is changing income into earnings. Standard ones embrace the gross margin, working margin and internet margin. Every stage reveals the place revenues are being depleted, with internet margin being the underside line.
Lastly, the EBITDA margin’s an excellent measure of how properly a enterprise converts income to money, with out the obscurity of unavoidable bills.
To indicate how this works in observe, I’ve utilized the evaluation to 2 of the perfect identified UK shares on the FTSE 100.
AstraZeneca
AstraZeneca (LSE: AZN) stands out as exceptionally worthwhile when evaluated utilizing the metrics mentioned above. The pharmaceutical firm demonstrates a internet revenue margin of 16.2%, considerably greater than most FTSE friends and properly above the sector median.
Extra impressively, its return on fairness (ROE) is round 22%, inserting it among the many highest within the index. This distinctive ROE displays the corporate’s effectivity at changing every pound of shareholder fairness into substantial revenue.
The corporate additionally maintains a robust working margin of 21.8%, indicating strong pricing energy and price management in its core pharmaceutical enterprise. For buyers looking for sustainable progress, it appears to be like an inexpensive inventory to contemplate.
Nonetheless, it isn’t with out danger. The approaching pharmaceutical patent cliff on its key drug Farxiga may drastically alter future income. The patent expires subsequent yr, placing in danger a possible $7.7bn in income. A number of different medication additionally face expiration earlier than 2030, together with Lynparza, so the corporate should proceed to innovate to stay related.
HSBC
When trying on the finance sector, we have to apply barely completely different metrics. In relation to banking, HSBC‘s (LSE: HSBA) extremely worthwhile when measured by return on tangible fairness (RoTE).
The financial institution achieved an annualised RoTE of 17.6% year-to-date in 2025, with some quarters reaching 16.4%. Whereas its conventional ROE stands at round 13%, which is respectable for banking, the RoTE metric is extra related for monetary establishments. It’s because it excludes goodwill and intangible property that distort profitability evaluation.
The financial institution’s sturdy profitability stems from various income streams, notably wealth administration, the place it demonstrated vital progress and excessive margins. However whereas it’s actually a compelling inventory to consider within the UK banking sector, it isn’t risk-free.
Earlier this yr, HSBC disbanded its devoted geopolitical danger crew, absorbing this perform into generalist departments as a cost-cutting measure. This resolution has drawn scrutiny, as analysis from the Financial institution for Worldwide Settlements (BIS) warns that banks underestimating geopolitical dangers face 30% greater earnings volatility throughout crises.
With opponents like JPMorgan Chase utilizing AI to increase its geopolitical consciousness, HSBC’s vulnerable to falling behind.
Nonetheless, with spectacular metrics backed by a long time of remarkable efficiency, it stays some of the worthwhile UK shares on the FTSE 100.
